MIMETAS

Most in vitro vascular models degrade within weeks. The OrganoPlate® Graft UniFlow available via our OrganoAccess platform changes the game: microvascular networks remain fully perfusable and continue to mature for at least 57 days in culture—a remarkable longevity that opens entirely new research possibilities. Why this matters: ✅ Chronic toxicity studies: Capture delayed vascular effects invisible to short-term assays ✅ Disease progression modeling: Study long-term pathophysiological changes in vascular systems ✅ Therapeutic efficacy: Evaluate compound effects over extended exposure periods ✅ Regulatory alignment: Generate data that reflects clinical exposure timescales With 57+ days of stable perfusion, you're no longer limited to acute snapshots. You can study the vascular biology that matters in drug development. Transform your toxicology program with long-term vascular models. Discover more https://lnkd.in/e4iMmb3H #OrganOnChip #VascularBiology #ToxicologyTesting #DrugDevelopment #Biotech

Human-relevant disease models start with mimicking human physiology. Our approach? Combine multiple cell types and let them self-organize under the right conditions. For our liver-on-chip platform this means combining hepatocytes, stellate cells, immune components like Kupffer cells, and vasculature on our OrganoPlate®️ microfluidic platform. The result: a liver model that closely mirrors real human tissue architecture and function. This is how we help you develop safer, more effective therapies. By modeling disease in systems that better represent human biology, we reduce attrition, accelerate development timelines, and bring better medicines to patients faster. Watch our webinar to see how multi-cellular complexity drives predictive power. https://lnkd.in/eWS_UytT #OrganOnChip #DrugDevelopment #PrecisionMedicine #Biotech #LiverModeling #NAMs

It is always inspiring to see the next generation of researchers exploring the potential of advanced in vitro models! 🧬 Yesterday, our colleagues Henriette Lanz, Usman and Camila joined the Utrecht Summer School on 'Advanced In Vitro Models: Organoids Meet Organs-on-a-Chip', where they delivered a 1.5-hour hands-on workshop introducing 26 participants to the OrganoPlate® platform. The session combined theory and practice. Participants first attended an insightful lecture by Renée Moerkens from Ombion Centre for Animal-free Biomedical Translation on the opportunities offered by organ-on-a-chip technologies. Henriette then introduced the OrganoPlate® platform before guiding participants through a hands-on demonstration, where they learned how to load ECM into an OrganoPlate® 3-lane 40, seed cells to create a tubular culture, and explore a range of downstream analyses. Beyond the practical training, the workshop also included interactive discussions around the participants' own research projects, brainstorming how human-relevant 3D in vitro models could help answer their scientific questions. A big thank you to the organizers of the Utrecht University Summer School for inviting us to be part of this year's programme, and to all participants for their enthusiasm and engaging discussions! #Ombion #HubMol #OrganoPlate #OrganOnAChip #AdvancedInVitroModels #3DCellCulture

A compromised intestinal epithelial barrier can trigger local and systemic inflammation, contributing to pathologies such as inflammatory bowel disease and celiac disease. Intestinal microbiota plays a key part in maintaining intestinal homeostasis. To further preserve the epithelial barrier in the gut, probiotics are being developed, yet their validation and selection require more suitable and human-relevant in vitro models. On Tuesday, July 21, join our speaker Ilia Belotserkovsky, PhD for a live webinar as he presents work on a developed gut-on-a-chip model in the OrganoPlate™ platform, used as a screening tool for probiotics and live biotherapeutics with homeostatic and immunomodulatory properties. Webinar highlights: - Using the OrganoPlate Platform to study inflammation and epithelial barrier damage - Inducing inflammatory processes in the model with inclusion of immune cells - Testing live probiotics and/or postbiotics for immunomodulatory or homeostatic potential in a high-throughput screening 👉 Reserve your spot here: https://lnkd.in/eARJJ-7Y #Webinar #InVitroModels #GutOnAChip #Immunocompetent

Tyrosine kinase inhibitors (TKIs) like Sorafenib are widely used in cancer therapy, but their vascular off-target effects are a clinical reality. Here's what's revealing: acute 72-hour exposure shows minimal vascular impact, yet chronic 21-day exposure drives significant vascular rarefaction. This disconnect between acute and chronic responses is precisely why long-term vascular models matter. Using the OrganoPlate® Graft UniFlow, available via our OrganoAccess™️ platform, we demonstrated: • Acute exposure (72 hours): No significant impact on vascular perfusion at clinically relevant concentrations • Chronic exposure (21 days): Progressive loss of perfusable vessel density, mirroring clinical vascular toxicity This mirrors the clinical picture: TKI-induced capillary bed toxicity emerges gradually in patients over time. Short-term assays entirely miss this critical safety signal. The lesson is clear: for cardiovascular safety assessment, long-term studies aren't optional—they're essential. Discover how chronic vascular toxicity models can transform your drug safety assessment https://lnkd.in/e9gqkMHG #OrganOnChip #ToxicologyTesting #CardiovascularSafety #DrugDevelopment #Biotech

Vascular inflammation is central to numerous diseases and drug-induced vascular toxicity. Yet most in vitro models fail to capture the dynamic interaction between endothelial cells and immune cells in a physiologically relevant context. The OrganoAccess microvasculature model is fully compatible with immune cell perfusion, enabling complete inflammatory response modeling: ✨ PBMC adhesion to activated endothelium following TNF-α stimulation 👾 Transendothelial migration of immune cells into the extracellular matrix 🔬 Endothelial barrier function assessment in inflammatory conditions ⏳ Long-term immune-vascular interactions over weeks This is a complete model for studying inflammation-driven endothelium–immune cell interactions—capturing the complexity of in vivo vascular immunology. Advance your immunology and inflammatory disease research with next-generation vascular models. Learn more https://lnkd.in/ewpivRix #OrganOnChip #Immunology #VascularBiology #Inflammation #DrugDevelopment

🎉 Big congratulations to Dr. Linda Gijzen on successfully defending her PhD dissertation at #UtrechtUniversity! Her thesis, "From Mechanism to Medicine: Advancing In Vitro Disease Models Using Microfluidics," focused on the development and application of advanced in vitro models for kidney and intestinal inflammatory diseases. Conducted at MIMETAS under the supervision of Dr. Henriette Lanz and Prof. Roos Masereeuw (Utrecht University), Linda's research demonstrates how human-relevant microphysiological systems can deepen our understanding of inflammatory disease mechanisms while helping address key limitations of traditional preclinical models. We are proud to have been part of Linda's PhD journey and are excited to see the impact her work will continue to have on the future of human-relevant research. Congratulations on this fantastic achievement, Linda, and we wish you all the best in your next chapter! 👏 #PhDDefense #OrgansOnAChip #MicrophysiologicalSystems #InVitroModels #InflammationResearch #WomenInSTEM #LifeSciences

Discover what's really in a NAM 🔬 Our webinar "What's in a NAM?" is available on demand! Join MIMETAS CEO & Co-founder Jos Joore as he breaks down New Approach Methodologies—what they are, why they matter, and how they're transforming drug development. Whether you're exploring alternatives to traditional animal testing or optimizing your safety assessment strategy, this session covers the essentials you need to know. Watch now: https://lnkd.in/ep7DyMCV #NAM #NewApproachMethodologies #DrugDevelopment #InVitro #Pharma #Biotech #Regulatory

The MIMETAS team based in Japan is attending JSOT 2026 (July 1–3), The 53rd Annual Meeting of the Japanese Society of Toxicology. Visit us at booth #16 to meet Yoko Ejiri, Yuki Ikeda and discuss human-relevant 3D tissue models and organ-on-a-chip applications! #JSOT2024 #Toxicology #JapaneseSocietyOfToxicology #OrganOnAChip

In organ-on-chip research, reproducibility is everything. A model is only as valuable as its consistency across experiments, operators, and laboratories. The OrganoAccess microvasculature model has been rigorously validated across independent experiments conducted by multiple operators in different laboraties. The result? Consistent network architecture, reliable performance, and minimal inter-experimental variation. Key findings: ✅ Vascular networks form reproducibly regardless of operator ✅ Vessel density and perfusability remain stable across experiments ✅ Performance meets industrial standards for adoption This isn't theoretical—it's validated science. When your research depends on reliable, reproducible results, you need a platform built for consistency. Discover the microvasculature model trusted by leading pharmaceutical researchers. 👉 https://lnkd.in/ehUyv7zM #OrganOnChip #Reproducibility #Validation #DrugDevelopment #Biotech